Crystal, pharmaceutical composition, preparation method therefor, and use thereof

HK40123031BActive Publication Date: 2026-09-11TYK MEDICINES INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK42025109467
Authority / Receiving Office
HK · HK
Patent Type
Patents
Current Assignee / Owner
Filing Date
2025-07-03
Publication Date
2026-09-11

AI Technical Summary

Technical Problem

The solubility and bioavailability of the existing TY-2136b compound are affected by pH dependence, resulting in uneven absorption and poor stability. There is a lack of suitable solid dosage forms for oral administration, and there is no effective crystal form study, which affects the drug's drugability and efficacy.

Method used

A monohydrate crystal form A of the compound of formula I was developed and prepared into an oral tablet containing specific diluents, disintegrants, gliding agents and lubricants to ensure rapid dissolution and high bioavailability under physiological pH conditions, while also exhibiting good storage stability.

Benefits of technology

It achieves rapid dissolution under physiological pH conditions, improving bioavailability, and maintains high dissolution under different storage conditions, ensuring drug stability and therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000031_0000
    Figure 00000031_0000
  • Figure 00000031_0001
    Figure 00000031_0001
  • Figure 00000032_0000
    Figure 00000032_0000
Patent Text Reader

Abstract

The present application relates to a pharmaceutical composition of the compound of formula I crystal form A, which has excellent storage stability and dissolution performance, and the crystal form A has good stability, reduced hygroscopicity and good bioavailability. The pharmaceutical composition and crystal form A are of great significance for improving the production, quality control and solid oral preparation development prospects of drugs, etc.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of medicinal chemistry technology, specifically relating to the crystal form of compounds used as kinase inhibitors, their preparation methods, and applications. Background Technology

[0002] The tropomyosin receptor kinase (TRK) family belongs to the transmembrane receptor tyrosine kinase (RTK) family and is involved in regulating synaptic growth and functional maintenance, memory development, and protecting neurons from damage in the mammalian nervous system. TRK kinases are a class of nerve growth factor receptors, and the family consists of highly homologous tropomyosin-related kinase A (TRKA), tropomyosin-related kinase B (TRKB), and tropomyosin-related kinase C (TRKC), encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. A complete TRK kinase comprises an extracellular domain, a transmembrane domain, and an intracellular domain. Like other RTKs, the extracellular domain of a TRK kinase binds to its corresponding ligand, forming a dimer that induces autophosphorylation of the intracellular domain, thereby activating its own kinase activity and further activating downstream signal transduction pathways. TRK kinases influence cell proliferation, differentiation, metabolism, and apoptosis through downstream pathways such as Ras / MAPK, PI3K / AKT, and PLCγ. When NTRK genes are fused or mutated, their extracellular receptors are altered or eliminated (Greco, A. et al., Mol. Cell. Biol. 1995, 15, 6118; Oncogene 1998, 16, 809). The fused or mutated TRK protein, without ligand binding, is in a highly activated kinase state, continuously activating downstream signal transduction pathways. This can lead to dysregulation of TRK kinase downstream signaling pathways, inducing cell proliferation and promoting tumor development and progression. NTRK gene fusions have been observed in various adult and pediatric solid tumors, including breast cancer, colorectal cancer, non-small cell lung cancer, papillary thyroid carcinoma, Spitz-like melanoma, glioma, and various sarcomas. In common cancers, such as non-small cell lung cancer and colorectal cancer, the incidence of NTRK gene fusion is low, approximately 1%-3%. However, in some rare cancers, such as infantile fibrosarcoma and secretory breast cancer, the incidence of NTRK gene fusion can reach over 90%. The earliest TPM3-TRKA fusion protein was discovered in colon cancer cells. Later, more types of NTRK fusion proteins, such as CD74-NTRKA, MPRIP-NTEKA, QKI-NTRKB, ETV6-NTRKC, and BTB1-NTRKC, were discovered in various clinical tumor patient samples, including breast cancer, non-small cell lung cancer, papillary thyroid carcinoma, Spitz-like melanoma, and glioma. Therefore, in recent years, NTRK fusion proteins have become an effective anti-cancer target and a hot topic in anti-cancer drug development.With a deeper understanding of TRK kinases in recent years, more TRK fusion protein types and mutation types have been discovered (Russo, M. et al. Cancer; Discovery, 2016, 6, 36; Drilon, A. et al. Annals of Oncology, 2016, 27, 920). Therefore, there is an urgent clinical need to develop novel NTRK inhibitors with better activity and broader effects to solve the treatment problems of tumors caused by these NTRK protein fusions or mutations.

[0003] ROS1 (c-ros oncogene 1 receptor kinase) is a tyrosine protein kinase encoded by the ROS1 proto-oncogene, located on chromosome 6q22.1. It belongs to the tyrosine kinase insulin receptor gene family and consists of three parts: an intracellular tyrosine kinase active domain, a transmembrane domain, and an extracellular domain. It encodes a chimeric protein with tyrosine kinase activity. Its basic structure comprises an extracellular N-terminal ligand-binding domain (amino acids 1-1861), a transmembrane domain (amino acids 1862-1882), and an intracellular C-terminal 464-amino acid tyrosine kinase active domain (amino acids 1883-2347). When the ROS1 gene undergoes rearrangement, the extracellular domain is lost, while the transmembrane domain and the intracellular tyrosine kinase domain are retained. Rearrangement sites mainly occur in exons 32-36 of the ROS1 gene. ROS1 gene mutations primarily occur in lung cancer patients, accounting for 1%-2% of cases. In NSCLC, the ROS1 gene primarily fuses with SLC34A2 and CD74, continuously activating the ROS1 tyrosine kinase domain and downstream signaling pathways such as JAK / STAT, PI3K / AKT, and RAS / MAPK, thereby leading to tumorigenesis. Numerous studies and clinical trials have confirmed that inhibiting the activity of mutated ROS1 kinases can treat diseases caused by ROS1 overactivation, especially cancer. Currently marketed drugs for treating ROS1-positive non-small cell lung cancer include crizotinib and entrectinib, both first-generation small-molecule ROS1 inhibitors. However, resistance to crizotinib or entrectinib develops and disease progresses after approximately 15 months of treatment. The most common resistance mutations in resistant patients are solvent-front mutations such as G2032R; currently, there are no treatments available for these resistant patients. Therefore, there is an urgent need to develop new ROS1 inhibitors, especially new ROS1 inhibitors for clinical treatment of patients who have developed resistance to first-generation ROS1 inhibitors such as crizotinib or entrectinib.

[0004] In NSCLC, 2-5% of cases are anaplastic lymphoma kinase (ALK) rearrangements. ALK is a receptor-type protein tyrosine phosphokinase belonging to the insulin receptor superfamily. ALK was initially discovered in anaplastic large cell lymphoma as an activated fusion oncogene. Subsequent studies have identified ALK fusion forms in various cancers, including systemic histiocytosis, inflammatory myofibroblastic carcinoma, and non-small cell lung cancer. The mutations and aberrant activity of ALK in various cancers have made it a potential drug target for treating ALK-positive cancers. Several ALK kinase inhibitors are currently on the market. However, with the clinical application of these drugs, patients often develop resistance mutations. For example, resistance mutations such as G1202R can render these drugs ineffective.

[0005] With a deeper understanding of kinases such as ROS1, NTRK, and ALK in recent years, and the increasing number of drug-resistant patients in clinical practice, there is an urgent need to develop novel tyrosine kinase inhibitors with better activity and broader effects to address the treatment of tumors caused by the fusion or mutation of kinase proteins such as ROS1, NTRK, and ALK.

[0006] Patent document CN112867717A discloses a kinase inhibitor capable of simultaneously acting on oncogenic proteins such as NTRK, ALK, and / or ROS1—compound TY-2136b as shown in Formula I, whose free base is chemically named (R)-3-(5,5-dimethyl-4,5-dihydro-1,2,4-oxadiazol-3-yl)-N-(1-(2,3,5-trifluorophenyl)ethyl)pyrazolo[1,5-a]pyrimidine-5-amine:

[0007]

[0008] Drugs need to be present in solution for absorption, but such precipitation can affect the extent and rate of absorption. Compounds with pH-dependent solubility (especially basic compounds) can exhibit undesirable pharmacokinetic properties, such as poor absorption or low bioavailability, leading to significant inter- and intra-patient variability. Therefore, there is a need to find an improved dosage form of TY-2136b with favorable dissolution and pharmacokinetic profiles and good storage stability.

[0009] No formulations for preparing the above-mentioned compound I have been reported. To deliver the therapeutic benefits of TY-2136b to patients in need, it is necessary to formulate TY-2136b into pharmaceutical compositions, particularly solid dosage forms suitable for oral administration. Therefore, a stable TY-2136b pharmaceutical formulation with good in vivo dissolution, high bioavailability, good storage stability, and accelerated stability is required.

[0010] Furthermore, no literature has been found reporting on the preparation of the crystal form of the compound of Formula I. Those skilled in the art understand that discovering compound forms favorable for the purification and quality control of pharmaceutical compounds is of great significance for improving the properties of drug production, quality control, and the development prospects of solid oral dosage forms. Since different drug crystal forms affect drug formulation properties, bioavailability, and efficacy, research on drug crystal forms is of great importance. Therefore, because the properties of TY-2136b, such as stability, flowability, drug formulation properties, quality control, and bioavailability, still need improvement, it is necessary to develop suitable forms of the above-mentioned compound and their preparation methods. Summary of the Invention

[0011] One or more embodiments of this application provide a pharmaceutical composition comprising:

[0012] Crystal form A of the monohydrate of compound I

[0013]

[0014] And pharmaceutically acceptable carriers, excipients or excipients;

[0015] The crystal form A has characteristic peaks at one or more of the following locations in the X-ray powder diffraction pattern expressed in 2θ angles: 9.35±0.2°, 11.42±0.2°, 12.06±0.2°, 18.71±0.2°, and 21.16±0.2°.

[0016] In one or more embodiments, the crystal form A also has characteristic peaks at one or more of the following locations in the X-ray powder diffraction pattern expressed in 2θ angles: 9.97±0.2°, 13.16±0.2°, 19.15±0.2°, 19.97±0.2°, and 21.00±0.2°.

[0017] In one or more embodiments, crystal form A has essentially the following characteristics: Figure 5 The X-ray powder diffraction pattern shown.

[0018] In one or more embodiments, the pharmaceutical composition is prepared as an oral formulation.

[0019] In one or more embodiments, crystal form A has essentially the following characteristics: Figure 6 The thermogravimetric analysis spectrum and differential scanning calorimetry spectrum are shown.

[0020] In one or more embodiments, the crystal form A is a monoclinic crystal system, space group P2(1), and the cell parameters are as follows: α=γ=90°β=93.349(8)°, deviation factor R1=0.0562, Z=4.

[0021] In one or more embodiments,

[0022] The pharmaceutical composition comprises the following components in parts by weight:

[0023] Components weight Crystal form A 2.5-40 First diluent 10-70 Second diluent 10-70 Flow aid 0.5-5 Disintegrant 1-15 lubricant 0.2-10 Coating material 1-10 .

[0024] In one or more embodiments, the D90 of crystal form A is 17-523 μm, for example, 17-191 μm;

[0025] In one or more embodiments, the first diluent is selected from mannitol, lactose, anhydrous dicalcium phosphate, or combinations thereof.

[0026] In one or more embodiments, the second diluent is microcrystalline cellulose.

[0027] In one or more embodiments, the flow aid is colloidal silica.

[0028] In one or more embodiments, the disintegrant is selected from sodium carboxymethyl starch, croscarmellose sodium, croscarmellose polyvinylpyrrolidone, or combinations thereof.

[0029] In one or more embodiments, the lubricant is selected from sodium stearate, magnesium stearate, or combinations thereof.

[0030] In one or more embodiments, the coating material comprises a stabilizing agent and a polymer, wherein the stabilizing agent is selected from at least one of titanium dioxide, talc, and yellow iron oxide, and the polymer is selected from at least one of polyvinyl alcohol and polyethylene glycol.

[0031] In one or more embodiments, the pharmaceutical composition has one or more of the following characteristics:

[0032] 1) Under conditions of pH 6.0-7.6 and 0.2% SDS, the dissolution rate of crystal form A in the pharmaceutical composition is ≥70% within 15 min;

[0033] 2) Under conditions of pH 6.0-7.6 and 0.2% SDS, the dissolution rate of crystal form A in the pharmaceutical composition is ≥85% within 45 min;

[0034] 3) Under conditions of pH 6.0-7.6 and 0.2% SDS, the dissolution rate of crystal form A in the pharmaceutical composition is ≥95% within 60 min;

[0035] 4) When the pharmaceutical composition is stored at 25±2℃ and 60%±5%RH for 18 months, the dissolution rate of crystal form A in the pharmaceutical composition is ≥85% within 45 minutes.

[0036] 5) When the pharmaceutical composition is stored at 40±2℃ and 75%±5%RH for 6 months, the dissolution rate of crystal form A in the pharmaceutical composition is ≥85% within 45 minutes.

[0037] One or more embodiments of this application provide a method for preparing the pharmaceutical composition of this application, comprising:

[0038] The following materials are provided in parts by weight as raw materials and said raw materials are prepared into a composition:

[0039] Components weight Crystal form A 2.5-40 First diluent 10-70 Second diluent 10-70 Flow aid 0.5-5 Disintegrant 1-15 lubricant 0.2-10 Coating material 1-10 .

[0040] In one or more embodiments,

[0041] Components weight Crystal form A 4-30 First diluent 20-60 Second diluent 20-60 Flow aid 1-4 Disintegrant 2-12 lubricant 0.5-10 Coating material 1.5-8 .

[0042] In one or more embodiments, the D90 of the crystal form A is 17-523 μm, for example, 17-191 μm.

[0043] In one or more embodiments, the first diluent is selected from mannitol, lactose, anhydrous dicalcium phosphate, or combinations thereof.

[0044] In one or more embodiments, the second diluent is microcrystalline cellulose.

[0045] In one or more embodiments, the flow aid is colloidal silica.

[0046] In one or more embodiments, the disintegrant is selected from sodium carboxymethyl starch, croscarmellose sodium, croscarmellose polyvinylpyrrolidone, or combinations thereof.

[0047] In one or more embodiments, the lubricant is selected from sodium stearate, magnesium stearate, or combinations thereof.

[0048] In one or more embodiments, the coating material comprises a stabilizing agent and a polymer, wherein the stabilizing agent is selected from at least one of titanium dioxide, talc, and yellow iron oxide, and the polymer is selected from at least one of polyvinyl alcohol and polyethylene glycol.

[0049] In one or more embodiments, the crystal form A is prepared by pulping the compound of formula I using a mixed solvent of acetonitrile and water.

[0050] In one or more embodiments, the crystal form A is prepared by slurrying the compound of formula I with a mixed solvent of acetonitrile and water for 1-4 days, and then collecting the crystalline powder solid by centrifugation.

[0051] One or more embodiments of this application provide the use of the pharmaceutical compositions of this application in the preparation of anticancer or antitumor drugs for treatment and / or prevention.

[0052] In one or more embodiments, the anticancer or antitumor drug targets cancers or tumors selected from breast cancer, cervical cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, peritoneal tumors, melanoma, glioma, glioblastoma, head and neck cancer, papillary renal tumor, leukemia, lymphoma, myeloma, and thyroid tumor.

[0053] One or more embodiments of this application provide the use of the pharmaceutical compositions of this application in the preparation of medicaments for treating and / or preventing ROS1, NTRK, and ALK-mediated diseases.

[0054] In one or more embodiments, the ROS1, NTRK, and ALK-mediated diseases are selected from cancer, sarcoma, and pain.

[0055] One or more embodiments of this application provide a pharmaceutical composition comprising the following components:

[0056] Component 1) Compound of Formula I

[0057]

[0058] Or its pharmaceutically acceptable hydrate, solvate or salt, as the active ingredient; and

[0059] Component 2) Pharmaceutically acceptable carrier.

[0060] In one or more embodiments, the pharmaceutical composition comprises the following components in parts by weight:

[0061] Composition weight weight weight weight Active ingredients 2.5-40 4-30 5-20 7.5-15 First diluent 10-70 20-60 25-55 30-50 Second diluent 10-70 20-60 25-55 30-50 Flow aid 0.5-5 1-4 1-3 1.5-3 Disintegrant 1-15 2-12 3-10 4-9 lubricant 0.2-10 0.5-5 0.5-3 0.5-2 Coating for weight gain 1-10 1.5-8 2-7 2-6

[0062] In one or more embodiments, the pharmaceutical composition has one or more characteristics selected from the following:

[0063] 1) Under conditions of pH 6.0-7.6 and 0.2% SDS (e.g., pH 6.2-7.4 or pH 6.5-7.2), the dissolution rate of the active ingredient in the pharmaceutical composition is ≥70% (e.g., ≥75%, ≥80%, ≥85%) within 15 min;

[0064] 2) Under conditions of pH 6.0-7.6 and 0.2% SDS (e.g., pH 6.2-7.4 or pH 6.5-7.2), the dissolution rate of the active ingredient in the pharmaceutical composition is ≥85% (e.g., ≥90%, ≥95%) within 45 min;

[0065] 3) Under conditions of pH 6.0-7.6 and 0.2% SDS (e.g., pH 6.2-7.4, pH 6.5-7.2), the dissolution rate of the active ingredient in the pharmaceutical composition is ≥95% (e.g., ≥98%, >100%) within 60 min;

[0066] 4) When stored at 25±2℃ and 60%±5%RH for 18 months, the dissolution rate of the active ingredient in the pharmaceutical composition is ≥85% (e.g., ≥90%, ≥95%) within 45 minutes;

[0067] 5) When stored at 40±2℃ and 75%±5%RH for 6 months, the dissolution rate of the active ingredient in the pharmaceutical composition is ≥85% (e.g., ≥90%, ≥95%) within 45 minutes.

[0068] In one or more embodiments, the pharmaceutically acceptable compound is a monohydrate.

[0069] In one or more embodiments, the pharmaceutical composition is an oral formulation.

[0070] In one or more embodiments, the pharmaceutical composition is in solid dosage form.

[0071] In one or more embodiments, the pharmaceutical composition is a tablet.

[0072] In one or more embodiments, the pharmaceutical composition further comprises a coating material.

[0073] In one or more embodiments, the weight of the coating material is 1.5-10% of the total weight of components 1) and 2), for example 1.8-8% or 2-6%.

[0074] One or more embodiments of this application provide a method for preparing the pharmaceutical composition of this application, comprising:

[0075] 1) Provide the following materials as raw materials;

[0076] Composition weight weight weight weight Active ingredients 2.5-40 4-30 5-20 7.5-15 First diluent 10-70 20-60 25-55 30-50 Second diluent 10-70 20-60 25-55 30-50 Flow aid 0.5-5 1-4 1-3 1.5-3 Disintegrant 1-15 2-12 3-10 4-9 lubricant 0.2-10 0.5-5 0.5-3 0.5-2 Coating material 1-10 1.5-8 2-7 2-6

[0077] 2) Prepare a pharmaceutical composition from the above materials.

[0078] In one or more embodiments, step 2) includes the following steps:

[0079] 2-1) Premix the active ingredient, first diluent, second diluent, glidant, disintegrant, and lubricant to obtain a premix;

[0080] 2-2) Dry granulation;

[0081] 2-3) The product obtained in step 2-2) is mixed with the second lubricant to obtain a total mixture;

[0082] 2-4) Compress the tablets to obtain plain tablets, which are the pharmaceutical composition.

[0083] In one or more embodiments, the hardness of the raw sheet is 40-150N, for example 70-130N or 80-120N.

[0084] In one or more embodiments, the hardness of the raw sheet is 30-100N, for example 40-90N or 50-80N.

[0085] One or more embodiments of this application provide the use of the pharmaceutical compositions of this application in the preparation of antitumor drugs.

[0086] In one or more embodiments, the tumor is any one of breast cancer, cervical cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumor, peritoneal tumor, melanoma, glioma, glioblastoma, head and neck cancer, papillary renal tumor, leukemia, lymphoma, myeloma, and thyroid tumor.

[0087] One or more embodiments of this application provide a crystal form A of the monohydrate of Formula I, which has characteristic peaks at one or more of the following locations in its X-ray powder diffraction pattern expressed in 2θ angles: 9.35±0.2°, 11.42±0.2°, 12.06±0.2°, 18.71±0.2°, and 21.16±0.2°. The chemical structural formula of the compound of Formula I is shown below:

[0088]

[0089] In one or more embodiments, the crystal form A also has characteristic peaks at one or more of the following locations in the X-ray powder diffraction pattern expressed in 2θ angles: 9.97±0.2°, 13.16±0.2°, 19.15±0.2°, 19.97±0.2°, and 21.00±0.2°.

[0090] In one or more embodiments, the X-ray powder diffraction of crystal form A, expressed at a 2θ angle, shows absorption peaks at the following positions.

[0091]

[0092]

[0093] In one or more embodiments, crystal form A has essentially the following characteristics: Figure 5 The X-ray powder diffraction pattern shown.

[0094] In one or more embodiments, the thermogravimetric analysis (TGA) spectrum of crystal form A shows a weight loss of 4.216% between room temperature (about 25°C) and 130°C.

[0095] In one or more embodiments, crystal form A has essentially the following characteristics: Figure 6 The thermogravimetric analysis spectrum is shown.

[0096] In one or more embodiments, the differential scanning calorimetry (DSC) spectrum of crystal form A has endothermic peaks at approximately 87.11 °C and 142.34 °C.

[0097] In one or more embodiments, crystal form A has essentially the following characteristics: Figure 6 The differential scanning calorimetry (DSC) spectrum is shown.

[0098] In one or more embodiments, crystal form A is a bulk crystal of 20-100 μm.

[0099] In one or more embodiments, crystal form A has essentially the following characteristics: Figure 7 The shape shown.

[0100] In one or more embodiments, the crystal form A is a monoclinic crystal system, space group P2(1), and the cell parameters are as follows: a=γ=90°β=93.349(8)°,deviation factor R1=0.0562,Z=4。

[0101] One or more embodiments of this application provide a method for preparing crystal form A, comprising: pulping a compound of formula I using a mixed solvent of acetonitrile and water.

[0102] In one or more embodiments, the volume ratio of acetonitrile to water is 1:(1 to 3), for example 1:1 or 1:2.

[0103] In one or more embodiments, pulping is performed at room temperature.

[0104] In one or more embodiments, crystal form A is prepared by the following method: Take the compound of formula I, add a mixed solvent of acetonitrile and water to conduct a pulping test, and after pulping for 1-4 days, collect the crystalline powder solid by centrifugation.

[0105] One or more embodiments of this application provide an amorphous form of a compound of formula I, which has a basic shape as shown in the figure. Figure 8The X-ray powder diffraction pattern shown.

[0106] One or more embodiments of this application provide a crystal form B of a compound of formula I, which has essentially the following characteristics: Figure 17 The X-ray powder diffraction pattern shown.

[0107] One or more embodiments of this application provide a crystal form C of a compound of formula I, which has essentially the following characteristics: Figure 18 The X-ray powder diffraction pattern shown.

[0108] One or more embodiments of this application provide a crystal form D of a compound of formula I, which has essentially the following characteristics: Figure 20 The X-ray powder diffraction pattern shown.

[0109] One or more embodiments of this application provide a crystal form E of a compound of formula I, which has essentially the following characteristics: Figure 9 The X-ray powder diffraction pattern shown.

[0110] One or more embodiments of this application provide the use of crystal form A of compound of formula I in the preparation of pharmaceutical compositions.

[0111] One or more embodiments of this application provide the use of crystal form A of a compound of formula I in the preparation of a medicament for the prevention and / or treatment of diseases mediated by pathological features such as ROS1, NTRK, and ALK.

[0112] In one or more embodiments, the diseases characterized by pathological features mediated by ROS1, NTRK, ALK, etc., include cancer, sarcoma, and pain.

[0113] In one or more embodiments, the cancer is any one of breast cancer, cervical cancer, colon cancer, lung cancer, stomach cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumor, peritoneal tumor, melanoma, glioma, glioblastoma, head and neck cancer, papillary renal tumor, leukemia, lymphoma, myeloma, and thyroid tumor.

[0114] In one or more embodiments, the crystal form A of the compound of formula I is used to prevent and / or treat the following diseases: inflammation, cancer, cardiovascular disease, infection, immune disease, and metabolic disease.

[0115] One or more embodiments of this application provide a treatment method comprising the steps of: administering crystal form A of the compound of formula I described in this invention to a subject requiring treatment for selectively inhibiting fusion mutations and drug resistance mutations of ROS1, NTRK, ALK, etc.

[0116] In one or more embodiments, crystal form A is of great significance for improving the properties of drug production, quality control, and the prospects for development of solid oral dosage forms.

[0117] In one or more embodiments, the physicochemical stability assessment results show that crystal form A is a monohydrate that does not lose water or have hygroscopic properties under normal conditions.

[0118] In one or more embodiments, the stability under high temperature, high humidity, accelerated testing, and light exposure is significantly better than that of amorphous and crystalline E.

[0119] In one or more embodiments, crystal form A has better fluidity than crystal form E and amorphous form.

[0120] In one or more embodiments, the bioavailability of crystal form A is significantly higher than that of amorphous form.

[0121] In one or more embodiments, crystal form A has great potential for further development and production due to its good physicochemical stability, flowability and bioavailability.

[0122] It should be understood that, within the scope of this invention, the above-described technical features and the technical features specifically described below can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0123] Figure 1 The dissolution curve is shown for tablet 1 obtained in Composition Example 1.

[0124] Figure 2 The dissolution curve is shown for tablet 2 obtained in Composition Example 2.

[0125] Figure 3 The dissolution curves of tablets 3 and 4 obtained from the actual compositions 3 and 4 are shown.

[0126] Figure 4 The dissolution profiles are for tablets 5-6 obtained from compositions 5-6.

[0127] Figure 5 This is the XRD pattern of crystal form A.

[0128] Figure 6 Thermogravimetric analysis and differential scanning calorimetry (TGA-DSC) for crystal form A.

[0129] Figure 7 This is a polarimetric micrograph (PLM) of crystal form A.

[0130] Figure 8 The XRD pattern is amorphous.

[0131] Figure 9 The image shows the XRD pattern of crystal form E.

[0132] Figure 10 The results are the DVS test results for crystal form A.

[0133] Figure 11 The results are from the DVS test of crystal form E.

[0134] Figure 12 The results are from the DVS test of the amorphous sample.

[0135] Figure 13 The flowability results are for crystal form A, crystal form E, and amorphous samples.

[0136] Figure 14 Blood concentration-time curves of rats administered 10 mg / kg of compound I (crystal form A).

[0137] Figure 15 Blood concentration-time curves of rats administered 10 mg / kg of compound I (amorphous).

[0138] Figure 16 The single crystal structure diagram of compound A of formula I is shown. Figure 16 The modified unit contains two molecules of the compound and one molecule of water of crystallization, wherein C7 and C7' are both in the R configuration and the FLACK parameter is 0.26 (12)).

[0139] Figure 17 This is the XRD pattern of crystal form B.

[0140] Figure 18 This is the XRD pattern of crystal form C.

[0141] Figure 19 Thermogravimetric analysis and differential scanning calorimetry (TGA-DSC) for crystalline C.

[0142] Figure 20 This is the XRD pattern of crystal form D.

[0143] Figure 21 Thermogravimetric analysis and differential scanning calorimetry (TGA-DSC) for crystal form D.

[0144] Figure 22 The XRD pattern of crystal form D after two days of closed storage at room temperature.

[0145] Figure 23 The XRD pattern of crystal form D after heating to 120°C and cooling to room temperature.

[0146] Figure 24 and Figure 25The XRD patterns of crystal forms A / C / D after suspension competition at different water activities at room temperature are shown. Detailed Implementation

[0147] The technical solution of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanatory of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.

[0148] Unless otherwise stated, the raw materials and reagents used in the following examples are commercially available products or can be prepared by known methods.

[0149] Through long-term and in-depth research, the inventors have obtained a pharmaceutical composition with excellent dissolution properties, pharmacokinetic properties, and storage stability by optimizing its composition. Based on this, the inventors have completed this invention.

[0150] Drugs can be absorbed at many different sites along the gastrointestinal tract (including via the stomach, duodenum, jejunum, ileum, and colon) after oral administration. The pH varies at each absorption site due to significant pH differences between the stomach (pH 1–3.5) and the small intestine (pH 4–8). Studies according to this application have found that the solubility of TY-2136b is pH-dependent, increasing with increasing pH, but generally low. Dissolution studies have shown that sink conditions are met in a pH 6.8 medium with added SDS.

[0151] One or more embodiments of this application provide pharmaceutical compositions suitable for oral administration, and more specifically relate to pharmaceutical compositions (e.g., pharmaceutical tablets) comprising TY-2136b or its pharmaceutically acceptable hydrates, solvates, or salts. Meanwhile, the solid dosage forms of the compositions of this application exhibit excellent storage stability.

[0152] In one or more embodiments, the pharmaceutical composition of this application can be formed into a tablet that exhibits improved solubility under physiologically relevant conditions and / or a higher total release of the pharmaceutical agent in physiologically relevant parameters.

[0153] Typically, crystallization produces solvates of the compounds of the present invention. As used herein, the term "solvate" refers to an aggregate comprising one or more molecules of TY-2136b and one or more solvent molecules. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as hydrates, including monohydrates, dihydrates, hemihydrates, sesquihydrates, trihydrates, tetrahydrates, etc., and the corresponding solvates.

[0154] "Pharmaceutical composition" refers to a formulation of the compounds of the present invention with a medium generally accepted in the art for the delivery of a biologically active compound into a mammal, such as a human. Such media include all pharmaceutically acceptable carriers, diluents, or excipients.

[0155] "Drug-acceptable carriers, diluents, or excipients" include, but are not limited to, any acceptable adjuvant, carrier, excipient, gliding agent, sweetener, diluent, preservative, dye / coloring agent, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier approved by the U.S. Food and Drug Administration for use in humans or domestic animals.

[0156] As used herein, the term "pharmaceutically acceptable salt" refers to a salt formed by the compounds of the present invention with an acid or base that is suitable for use as a medicine. Pharmaceutically acceptable salts include both inorganic and organic salts. A preferred class of salts are those formed by the compounds of the present invention with an acid. Suitable acids for forming salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid.

[0157] Another preferred class of salts are salts formed by the compounds of the present invention with a base, such as alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., magnesium or calcium salts), ammonium salts (such as lower alkanol ammonium salts and other pharmaceutically acceptable amine salts), such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0158] Because TY-2136b has excellent anti-tumor activity, pharmaceutical compositions containing TY-2136b as the main active ingredient can be used to treat, prevent, and alleviate tumor-related diseases.

[0159] The pharmaceutical composition of this application comprises the compound of the present invention or its pharmacologically acceptable salt and a pharmacologically acceptable excipient or carrier within a safe and effective range. "Safe and effective range" refers to an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably, 10-1000 mg of the compound of the present invention per dose. Preferably, "one dose" is one capsule or tablet.

[0160] "Pharmaceutically acceptable carriers" refers to one or more compatible solid or liquid fillers or gelling substances that are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with and with the compounds of the present invention without significantly reducing the efficacy of the compounds. Examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as... Wetting agents (such as sodium dodecyl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0161] The pharmaceutical composition of this application is an injection, capsule, tablet, pill, powder or granule.

[0162] There are no particular limitations on the administration of the compounds or pharmaceutical compositions of the present invention. Representative administration methods include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and local administration.

[0163] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following components: (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol, and silica; (b) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or cassava starch, alginate, certain complex silicates, and sodium carbonate; (e) slowing agents, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. Buffers may also be included in capsules, tablets, and pills.

[0164] Solid dosage forms such as tablets, sugar pills, capsules, pellets, and granules can be prepared using coatings and shells, such as casings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compound from such compositions can be delayed in a portion of the digestive tract. Examples of encapsulating components that can be used are polymeric substances and waxes. If necessary, the active compound may also be formed into microcapsules with one or more of the excipients described above.

[0165] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, e.g., ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.

[0166] In addition to these inert diluents, the composition may also contain auxiliaries such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and fragrances.

[0167] In addition to the active compound, the suspension may contain suspending agents such as ethoxylated isooctadecyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitol esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.

[0168] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents, or excipients include water, ethanol, polyols, and suitable mixtures thereof.

[0169] Dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays, and inhalers. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be necessary.

[0170] The compositions of the present invention can be administered alone or in combination with other pharmaceutically acceptable compositions (such as antitumor drugs).

[0171] The treatment method of the present invention can be used alone or in combination with other treatment methods or drugs.

[0172] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to the mammal (such as a human) requiring treatment, wherein the dose administered is the pharmaceutically considered effective dose. For a person weighing 60 kg, the daily dose is typically 1-2000 mg, preferably 50-1000 mg. The specific dose should also take into account factors such as the route of administration and the patient's health condition, which are all within the scope of the skill of a skilled physician.

[0173] Specific embodiments of the present invention describe in detail the preparation methods of the pharmaceutical compositions of the present invention, but these specific methods do not constitute any limitation on the present invention. The pharmaceutical compositions of the present invention can also be conveniently prepared by optionally combining various preparation methods described in this specification or known in the art, such combinations being readily performed by those skilled in the art.

[0174] Typically, the raw materials and reagents used in the preparation process of the pharmaceutical compositions of the present invention can be purchased commercially unless otherwise specified.

[0175] In one or more embodiments, the pharmaceutical composition of this application has one or more of the following beneficial effects:

[0176] (1) The pharmaceutical composition has excellent dissolution properties, pharmacokinetic properties and storage stability;

[0177] (2) The pharmaceutical composition is of stable quality;

[0178] (3) The preparation process of the pharmaceutical composition is simple and easy to implement, and is convenient for industrial production.

[0179] (4) The pharmaceutical composition is convenient to administer, safe and reliable to use, and easily accepted by patients, and has high social and economic value.

[0180] Example

[0181] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.

[0182] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as are familiar to those skilled in the art. Furthermore, any methods and materials similar to or equivalent to those described herein may be applied to the methods of this invention. The preferred embodiments and materials described herein are for illustrative purposes only.

[0183] Examples of the composition

[0184] General raw materials

[0185]

[0186]

[0187] General Method

[0188] Dissolution performance

[0189] Dissolution rate refers to the rate and extent to which a drug dissolves from a solid dosage form, such as a tablet, in a specified solvent. Dissolution rate is an important indicator for tablet quality control, and it is generally required to test the dissolution rate of poorly soluble drugs. The dissolution test method involves placing a specific quantity of a solid dosage form into the rotating basket (or dissolution vessel) of a dissolution apparatus, maintaining a constant temperature of 37℃±0.5℃, operating at a specified rotation speed and in a specified dissolution medium, and taking samples within a specified time to determine the amount dissolved.

[0190] The dissolution test conditions are as follows:

[0191] Dissolution medium: pH 6.8 phosphate buffer + 0.2% SDS

[0192] Dissolution medium volume: 900ml

[0193] Speed: 50 rpm (the final speed is 250 rpm from 60 to 75 minutes)

[0194] Water bath temperature: 37±0.5℃

[0195] Sampling time points: 5, 15, 30, 45, 60, 75 min

[0196] Composition Example 1: Tablet 1 and its preparation (Formulation composition (40 mg))

[0197] Raw material names Specific gravity % (w / w) mg / tablet Function TY-2136b (D90 17.00μm) 10.46 41.85 Drug substances lactose 39.77 159.08 diluent microcrystalline cellulose 39.77 159.08 diluent colloidal silica 2.00 8.00 Flow aid Cross-linked carboxymethyl cellulose sodium 7.00 28.00 Disintegrant Magnesium stearate (added internally) 0.50 2.00 lubricant Magnesium stearate (added) 0.50 2.00 lubricant Total of raw slices 100.00 400.00 Film-coated premix (gastric-soluble) 3.00 12.00 Coating Total of coated sheets 103.00 412.00

[0198] Note: The TY-2136b used contains one molecule of water, and 41.85 mg of hydrate is equivalent to 40 mg of free TY-2136b base.

[0199] Tablets 1 were manufactured using a dry mixing / crushing process and the materials listed in the table above. TY-2136b, colloidal silica, cross-linked sodium carboxymethyl cellulose, and microcrystalline cellulose were each sieved through a 40-mesh sieve and then sequentially added to the mixing hopper. The mixing speed was set to 20 rpm, and the mixture was mixed for 25 minutes. Magnesium stearate (internal addition) was added to the mixing hopper, and the mixing speed was set to 20 rpm, and the mixture was mixed for 5 minutes to obtain a premix. The premix was then added to a dry granulator for dry granulation. The feed speed was 20-30 rpm, the forming pressure was 25-35 bar (specifically 30 bar), the pressure roller speed was 10-20 rpm (specifically 15 rpm), and the granulation speed was 120-180 rpm (specifically 150 rpm) to obtain dry-granulated granules. The granules collected after dry granulation and the sieved magnesium stearate (external addition) were added to the mixing hopper, and the mixing speed was set to 20 rpm for 5 minutes (i.e., total mixing time). Using this mixture, press the tablets, and use a punch to press the sheet 1 (hardness 81-115N).

[0200] A 12% (w / w) coating suspension was prepared from a film coating premix (12 mg / tablet) and coated with unprocessed tablet 1 at 3% of the unprocessed tablet weight to form tablet 1.

[0201] The dissolution results of the obtained tablet 1 are shown in Table 1 below.

[0202] Table 1

[0203] Time (min) 0 5 15 30 45 60 75 Dissolution rate (%) 0 41 83 93 97 99 102

[0204] Figure 1 The dissolution curve is for tablet 1 obtained in Example 1.

[0205] like Figure 1 As shown in Table 1 above, tablet 1 was able to dissolve completely under the above dissolution conditions, and the dissolution rate reached 97% of the labeled amount after 45 minutes, which meets the standard.

[0206] Composition Example 2: Tablet 2 and its preparation (Formulation composition (10 mg))

[0207] Raw material names Specific gravity % (w / w) mg / tablet Function TY-2136b (D90 17.00μm) 10.46 10.46 Drug substances lactose 39.77 39.77 diluent microcrystalline cellulose 39.77 39.77 diluent colloidal silica 2.00 2.00 Flow aid Cross-linked carboxymethyl cellulose sodium 7.00 7.00 Disintegrant Magnesium stearate (added internally) 0.50 0.50 lubricant Magnesium stearate (added) 0.50 0.50 lubricant Total of raw slices 100.00 100.00 Film-coated premix (gastric-soluble) 3.00 3.00 Coating Total of coated sheets 103.00 103

[0208] Note: The TY-2136b used contains one molecule of water, and 10.46 mg of hydrate is equivalent to 10 mg of free TY-2136b base.

[0209] Tablets 2 were manufactured using a dry mixing / crushing process and the materials listed in the table above. TY-2136b, colloidal silica, cross-linked sodium carboxymethyl cellulose, and microcrystalline cellulose were each sieved through a 40-mesh sieve and then sequentially added to the mixing hopper. The mixing speed was set to 20 rpm, and the mixture was mixed for 25 minutes. Magnesium stearate (internal addition) was added to the mixing hopper, and the mixing speed was set to 20 rpm, and the mixture was mixed for 5 minutes to obtain a premix. The premix was then added to a dry granulator for dry granulation. The feed speed was 20-30 rpm, the forming pressure was 25-35 bar (specifically 30 bar), the pressure roller speed was 10-20 rpm (specifically 15 rpm), and the granulation speed was 120-180 rpm (specifically 150 rpm) to obtain dry-granulated granules. The granules collected after dry granulation and the sieved magnesium stearate (external addition) were added to the mixing hopper, and the mixing speed was set to 20 rpm for 5 minutes (i.e., total mixing time). Using this mixture, press the tablets, and use a punch to press the sheet 2 (hardness 53-78N).

[0210] A 12% (w / w) coating suspension was prepared by preparing a film coating premix (3 mg / tablet) and coating the unprocessed tablet 2 with 3% of the unprocessed tablet weight to form tablet 2.

[0211] Table 2

[0212] Time (min) 0 5 15 30 45 60 75 Dissolution rate (%) 0 59 82 93 97 98 99

[0213] Figure 2 The dissolution curve is for tablet 2 obtained in Example 2.

[0214] like Figure 2 As shown in Table 2 above, tablet 2 can be completely dissolved under the above dissolution conditions, and the dissolution rate reaches 97% of the labeled amount after 45 minutes, which meets the standard.

[0215] Composition Examples 3-4 Tablets 3 and 4

[0216] Similar to Example 1, the main difference lies in the amount of disintegrant used, as shown in Table 3 below, and the dissolution results are shown in Table 4 below.

[0217] Table 3. Formulation composition with different disintegrant dosages

[0218]

[0219]

[0220] Table 4. Effect of different disintegrant dosages on dissolution rate

[0221]

[0222] like Figure 3As shown in Table 4 above, tablet 4 was able to dissolve completely under the above dissolution conditions, and the dissolution rate reached 84% of the labeled amount after 45 minutes, which meets the standard.

[0223] Composition Examples 5-6 Tablets 5-6

[0224] Same as Example 3, except that the particle size of TY-2136b in the formula is different, and the process uses direct powder pressing, as shown in Table 5 below. The dissolution rate is shown in Table 6 below.

[0225] Table 5 Formulation composition for different API particle sizes

[0226]

[0227] Table 6. Effect of API Particle Size on Dissolution Rate

[0228]

[0229] like Figure 4 As shown in Table 6 above, tablets 5-6 can be completely dissolved under the above dissolution conditions, and the dissolution rate reaches more than 80% of the labeled amount after 45 minutes, which meets the standard.

[0230] Composition Example 7

[0231] The inventors produced tablets 1 (40 mg) and tablets 2 (10 mg) according to the formulations in Examples 1 and 2. The above samples were placed at 40℃ / 75%RH (open), 40℃ / 75%RH (closed), and 40℃ / 75%RH (closed + 1 g desiccant) respectively to investigate dissolution and related substances. The results are shown in Tables 7 and 8 below.

[0232] Table 7 shows the dissolution results of the samples in the stability study.

[0233] Table 7

[0234]

[0235] Table 8 shows the results of the stability study of the relevant substances in the samples.

[0236] Table 8

[0237]

[0238] Note: *1. The results for this raw material are from the same sequence as the results for the two specifications T0, 40℃ / 75%RH (open) 10 days and 40℃ / 75%RH (closed) 10 days.

[0239] *2. The results for this raw material are from the same sequence as the results for the two specifications at 40℃ / 75%RH (closed mouth + 1g desiccant) for 30 days.

[0240] As shown in Table 7, the dissolution rates of tablet 1 (40 mg) and tablet 2 (10 mg) did not change significantly after being stored at 40℃ / 75%RH (open) and (closed + 1 g desiccant) for 30 days, which is in line with the Chinese Pharmacopoeia.

[0241] As shown in Table 8, when tablets 1 (40 mg) and tablets 2 (10 mg) were stored for 30 days at 40℃ / 75%RH (open), 40℃ / 75%RH (closed), and 40℃ / 75%RH (closed + 1 g desiccant), the individual impurities fluctuated within acceptable ranges.

[0242] Examples of crystal forms

[0243] Crystal Form Example 1: Preparation of Crystal Form A

[0244] 15.3 mg of compound I was placed in a 1.5 mL HPLC flask, and 0.2 mL of ACN / H₂O (1:1, v:v) was added for a slurry preparation at room temperature. After slurry preparation for approximately 4 days, the crystalline powder solid was collected by centrifugation, which is crystal form A. Its XRD pattern is shown below. Figure 5 As shown. Thermogravimetric analysis and differential scanning calorimetry (TGA-DSC) are as follows. Figure 6 As shown. Polarizing microscopy spectra (PLM) are as follows. Figure 7 As shown.

[0245] Table 9 XRPD Test Parameters

[0246]

[0247] The single crystal structure diagram of crystal form A is shown below. Figure 16 As shown. Single crystal data: monoclinic system, space group P2(1), cell parameters are... α=γ=90°β=93.349(8)°, deviation factor R1=0.0562, Z=4.

[0248] Crystal Form Example 2: Preparation of Amorphous Crystals

[0249] Weigh 400 mg of the crystal form A sample prepared in Example 1, dissolve it in 20 mL of dichloromethane at room temperature, filter, and then rapidly remove the solvent from the filtrate by rotary evaporation. Perform the corresponding characterization tests on the obtained solid sample. Its XRD pattern is shown below. Figure 8 As shown in the figure, after the amorphous sample was left overnight under environmental conditions (room temperature, >20% RH), PLM was observed again, and it was found that some samples had transformed into crystals. After the sample was left under the same conditions for two more days, XRD results showed that the crystal form of the transformed sample was basically consistent with crystal form A. The above results show that the amorphous sample is unstable under environmental conditions and recrystallizes into crystal form A after absorbing moisture.

[0250] Crystal Form Example 3: Preparation of Crystal Form E

[0251] Crystal form E was obtained by suspending and stirring the amorphous sample prepared in Example 2 in a 1,4-dioxane / n-heptane solvent system at room temperature. XRD results are as follows: Figure 9 As shown, the results indicate that the E-type sample transforms into the A-type sample after being air-dried at room temperature for about one day, suggesting that the E-type sample is a metastable crystal form.

[0252] Crystal Form Example 4: Preparation of Crystal Form B

[0253] Crystal form B was obtained by purging the starting crystal form A sample under nitrogen (approximately 5% RH) for 2 hours. XRD results are shown below. Figure 17 Because the sample rapidly changed to crystal form C under ambient humidity conditions (17.3% RH) on the same day, it is presumed to be a metastable crystal form.

[0254] Crystal Form Example 5: Preparation of Crystal Form C

[0255] Crystal form C was obtained by purging the starting crystal form A sample under nitrogen (approximately 5% RH) for 2 hours and then placing it at room temperature (17.3% RH) for 2 hours. Its XRD results are shown in [Figure number missing]. Figure 18 TGA / DSC results are as follows: Figure 19 As shown, the results indicate that the sample lost 3.2% of its weight when heated from room temperature to 150℃, and exhibited endothermic peaks at 57.5℃, 94.5℃, and 138.4℃ (peak temperature). Crystal form C... 1 The 1H NMR spectrum was obtained in DMSO-d6, and no obvious solvent residue was observed. Since crystal form C was obtained by increasing the humidity of crystal form B, combined with the obvious step-like weight loss in the TGA curve and the endothermic signal in the DSC curve, it was initially inferred that crystal form C is a hydrate. Multiple attempts were made to prepare crystal form C, but pure crystal form C samples were not obtained.

[0256] Crystal Form Example 6: Preparation of Crystal Form D

[0257] Crystal form D sample was obtained by slow evaporation of the starting sample crystal form A in methanol solvent. Its XRD results are shown in [Figure number missing]. Figure 20 TGA / DSC results are as follows: Figure 21 As shown, the results indicate that the sample lost 2.6% of its weight when heated from room temperature to 150°C, and exhibited an endothermic peak at 83.4°C (peak temperature). Crystal form D... 1 The 1H NMR spectrum was obtained in DMSO-d6, and no obvious solvent residue was observed. Figure 22 As shown, after two days of closed storage at room temperature, the crystallinity of crystal form D sample decreased significantly; as Figure 23 As shown, after heating to 120℃ and cooling to room temperature, the sample transforms into an amorphous form. Based on the NMR data of the sample and the results of the heating experiment, it is inferred that crystal form D is a hydrate crystal form.

[0258] Crystal form test example 1: Evaluation of crystal form solubility and hygroscopicity

[0259] The approximate solubility of crystal form A in different organic solvents at room temperature is as follows:

[0260] solvent Solubility (mg / mL) methanol S>36.0 ethanol S>38.0 Isopropanol S>42.0 dichloromethane S>40.0 chloroform S>44.0 Acetonitrile S>44.0 acetone S>40.0 Methyl isobutyl ketone S>40.0 Ethyl acetate S>44.0 Isopropyl acetate S>38.0

[0261] The hygroscopicity of different crystalline forms of active pharmaceutical ingredients was studied using dynamic moisture adsorption (DVS) analysis.

[0262] Measurement method:

[0263] Instrument: Dynamic water vapor adsorption apparatus; Temperature: 25℃; Protective gas and flow rate: N2, 200mL / min;

[0264] dm / dt: 0.002% / min; RH range: 0%RH-100%RH; Cycle: 1 complete cycle.

[0265] Experimental results:

[0266] The DVS experimental results for crystal form A are shown in the figure. Figure 10 .from Figure 10 It can be seen that when the humidity is 0%, the weight loss of crystal form A sample is about 3-4%, which is comparable to the weight loss of the water of crystallization. The weight gain is significant when the humidity increases from 0% to 20%, almost no weight gain occurs when the humidity increases from 20% to 80%, and significant moisture absorption occurs above 90%. Weight loss continues as the humidity decreases from 100% to 0%, and the weight change trajectories of adsorption and desorption completely overlap.

[0267] The DVS experimental results for crystal form E are shown in [reference needed]. Figure 11 .Depend on Figure 11 It can be seen that the E-type sample experienced continuous weight loss as humidity increased from 0% to 90%: approximately 2% weight loss from 0% to 30% humidity, and a sudden weight loss from 40% to 50% humidity. From 90% to 100% humidity, the weight gained through moisture absorption was approximately 4%; from 100% to 90% humidity, the weight loss was approximately 2%, with the weight gain from moisture absorption exceeding the weight loss. At humidity below 20%, the weight loss was significant, reaching 3%. The weight change trajectories of adsorption and desorption were largely non-overlapping.

[0268] The experimental results for amorphous DVS are shown in Figure 12 .Depend on Figure 12It can be seen that the amorphous sample continuously gains weight as humidity increases from 0% to 100%; the weight gain rate is uniform from 0% to 80% humidity, and abruptly increases weight from 80% to 100% humidity. The weight gain from 90% to 100% humidity is approximately 3.5%. Conversely, the amorphous sample continuously loses weight as humidity decreases from 100% to 0% humidity; the weight loss rate is rapid from 100% to 90% humidity, approximately 1.5%, which is less than the weight gain; the weight loss rate is uniform from 90% to 0% humidity. The adsorption and desorption weight change trajectories do not overlap at all.

[0269] In summary, crystal form A is a monohydrate, which does not lose water or exhibit hygroscopic properties under normal conditions; crystal form E is a solvate, which will lose its solvent under normal environmental humidity changes and is hygroscopic; the amorphous form is hygroscopic. Therefore, crystal form A exhibits significantly better stability under normal storage and production conditions than crystal form E and the amorphous form.

[0270] Crystal form test example 2: Evaluation of crystal form transformation relationship

[0271] For samples of crystal forms A, C, and D that are relatively stable at room temperature, the transformation relationship between crystal forms was studied through a suspension competition experiment at different water activities at room temperature. The initial crystal form A sample was vacuum dried at room temperature and used to prepare saturated solutions of acetone / water at different water activities. After pre-equilibration for 8 to 24 hours, the solution was filtered through a PTFE membrane with a pore size of 0.45 μm. The filtrate was transferred to HPLC vials containing samples of crystal forms A, C, and D. After suspension and stirring at room temperature, the solid wet samples were separated for XRD (coating assay). The results are summarized in Table 10, and the XRD patterns are shown below. Figure 24 and Figure 25 The results showed that crystal form A was obtained in all systems.

[0272] Table 10 Suspension Competition Test Results Among Crystal Forms A / C / D

[0273]

[0274] Crystal form test example 3: Physicochemical stability assessment

[0275] To verify the stability of crystal form A, crystal form E, and amorphous form, high temperature, high humidity, accelerated testing, and light irradiation experiments were also conducted. The specific test methods and results are shown below.

[0276] 3.1 High Temperature Test

[0277] The high-temperature test methods are shown in Table 11 below.

[0278] Table 11

[0279]

[0280] 3.2 The high humidity test method is shown in Table 12 below.

[0281] Table 12

[0282]

[0283] 3.3 Illumination Test

[0284] The methods for conducting light exposure tests are shown in Table 13 below.

[0285] Table 13

[0286]

[0287] 3.4 Accelerated Testing

[0288] The accelerated testing methods are shown in Table 14 below.

[0289] Table 14

[0290]

[0291]

[0292] The results of relevant substances in each crystal form under high temperature conditions (50℃±2℃) are shown in Table 15.

[0293] HPLC detection results of related substances under high temperature conditions:

[0294] Table 15

[0295]

[0296] After being placed at high temperature (50℃±2℃) for 32 days, the content of specific impurity RRT0.66 showed no significant change (increase ≤0.02%) in crystal form A with prolonged high temperature time, while the content increased by 0.05% in crystal form E. The content of specific impurity RRT0.71 showed no significant change in either crystal form with prolonged high temperature time. Specific impurity RRT1.02 showed no significant change in crystal form A, but increased by 0.19% in crystal form E. Specific impurity RRT1.08 increased by 0.05% in crystal form A and 0.23% in crystal form E. The content of other non-specific impurities was no greater than 0.10%. The total impurities increased by 0.16% and 0.51% in crystal form A and crystal form E, respectively, and the total impurity content was no greater than 2.0% in both forms. In summary, under high temperature conditions, crystal form A exhibits superior stability compared to crystal form E.

[0297] The results of relevant substances in each crystal form under high humidity conditions (90%RH±5%RH) are shown in Table 16.

[0298] The HPLC detection results of related substances under high humidity conditions are shown below:

[0299] Table 16

[0300]

[0301] After being stored under high humidity conditions (90%RH ± 5%RH) for 32 days, the contents of specific impurities RRT0.66 and RRT0.71 remained essentially unchanged in all three crystal forms (increase ≤ 0.02%). Specific impurity RRT1.02 remained essentially unchanged in crystal forms A and E, but increased by 0.03% in the amorphous form. Specific impurity RRT1.08 remained essentially unchanged in crystal form A, but increased by 0.04% and 0.05% in crystal form E and the amorphous form, respectively. The contents of other non-specific impurities were all less than 0.10%, and the total impurities increased by 0.03%, 0.05%, and 0.10% in crystal forms A, E, and the amorphous form, respectively, with the total impurity content not exceeding 2.0% in all forms. In summary, under high humidity conditions, crystal form A exhibits better stability than crystal forms E and the amorphous form.

[0302] The results of relevant substances in each crystal form under illumination conditions (4500 lx ± 500 lx) are shown in Table 17.

[0303] The HPLC detection results of related substances under illumination are shown below:

[0304] Table 17

[0305]

[0306] Note: ND indicates not detected.

[0307] After 32 days of exposure to light (4500 lx ± 500 lx), the content of specific impurity RRT0.66 increased in crystal form A, crystal form E, and amorphous forms, by 0.09%, 0.04%, and 0.03%, respectively. Specific impurities RRT0.71 and RRT1.02 showed no increase in crystal form A and crystal form E, but increased by 0.05% and 0.06%, respectively, in amorphous forms. Specific impurity RRT1.08 increased by 0.09%, 0.08%, and 0.19% in crystal form A, crystal form E, and amorphous forms, respectively. The content of other non-specific impurities was no greater than 0.10%, and the total impurities increased by 0.13%, 0.13%, and 0.37% in crystal form A, crystal form E, and amorphous forms, respectively, with the total impurity content no greater than 2.0%. In summary, crystal form A and crystal form E exhibit better stability than amorphous forms under light exposure.

[0308] The results of the changes in relevant substances in each crystal form under accelerated conditions (40℃±2℃, 75%RH±5%RH) are shown in Table 18.

[0309] The HPLC detection results of related substances under accelerated conditions are shown below:

[0310] Table 18

[0311]

[0312] After 32 days of accelerated storage (40℃±2℃, 75%RH±5%RH), the specific impurities RRT0.66, RRT0.71, and RRT1.02 showed no significant changes (increase ≤0.02%) in the three crystal forms. The specific impurity RRT1.08 increased by 0.04%, 0.03%, and 0.03% in crystal forms A, E, and amorphous, respectively, with comparable increases. The contents of other non-specific impurities were all no greater than 0.10%, and the total impurities were all no greater than 2.0%. This indicates that the stability of the three crystal forms is comparable under accelerated storage conditions.

[0313] Under high temperature (50℃±2℃) and high humidity (90%RH±5%RH) conditions, crystal form A exhibits better stability than crystal form E and the amorphous form, respectively. Under illumination (4500lx±500lx), both crystal forms A and E show better stability than the amorphous form. Under accelerated conditions (40℃±2℃, 75%RH±5%RH), the stability of the three crystal forms is comparable. Compared to other conditions, the stability of all three crystal forms is poor under illumination (4500lx±500lx), suggesting that they should be stored away from light.

[0314] In summary, compared to crystal form E and amorphous crystals, crystal form A is the most stable crystal form and the most suitable for subsequent processing and development.

[0315] Crystal form test example 4: Flowability test

[0316] The flowability test method is as follows: Use a device with 2 to 3 funnels connected in staggered series to measure the angle of repose. The drug powder flows slowly and evenly through the funnels to a stationary base with a diameter of d, forming a symmetrical powder pile with a single layer of powder at the bottom. During the formation of the powder pile, the height of the funnel must be maintained within 2 to 4 cm from the top of the powder pile. Measure the height h of the cone and calculate the angle of repose tanθ = h / (d / 2).

[0317] Experimental results: The powder flowability test results for the three crystalline drug substances are shown in the figure. Figure 13 .

[0318] The test results showed that the angle of repose of crystal form A sample was approximately 32.7°, the angle of repose of crystal form E sample was 37.9°, and the angle of repose of amorphous sample was approximately 37.5°.

[0319] Since the smaller the angle of repose of the powder, the better its flowability, crystal form A has better flowability than crystal form E and amorphous form.

[0320] Crystal form test example 5 Pharmacokinetic test

[0321] This test case compared the pharmacokinetic processes of crystalline A and amorphous forms in SD rats, and compared their pharmacokinetic characteristics in SD rats.

[0322] Experimental methods and materials

[0323] Compound information

[0324] test substance

[0325] Name: Compound of Formula I (Crystal Form A)

[0326] Name: Compound of Formula I (Amorphous)

[0327] Internal Standard

[0328] Name: Verapamil

[0329] Experimental animals: Six healthy adult male SD rats, divided into two groups of three, aged 6-8 weeks; weighing approximately 200-300 grams. Animals were housed in rat cages and fasted for at least 10 hours prior to the experiment, but allowed free access to water. On the day of the experiment, each rat was weighed and marked on its tail. Blank blood samples were collected before drug administration. Blood was collected via tail vein. Administration method: Oral administration (po): Drug suspension was administered via gavage. Preparation of the drug suspension: Accurately weigh approximately 10 mg of the sample to be tested, dissolve in 5% DMSO (converted to 5%), vortex with 10% Solutol HS-15 and 85% Saline to obtain a suspension with a concentration of 1.0 mg / mL; freshly prepared before use.

[0330] Sample collection: Rats were orally administered 10 mg / kg via gavage. Timing began immediately after administration, and blood samples were collected at 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-administration. 0.1 ml of whole blood was collected into EDTA-Na2 anticoagulant tubes, inverted 3-4 times to mix, and centrifuged at 10000g for 5 min at 4℃ to separate plasma. The plasma was stored at -80℃ for later analysis. Blood was collected via tail vein.

[0331] Sample preparation: 1) Thaw the samples and take 15 μL each of the unknown plasma sample before or after drug administration, standard series solutions, single blank, and double blank samples into 1.5 ml centrifuge tubes. 2) Add 15 μL of protein precipitant (methanol) and 400 μL of internal standard solution (verapamil prepared in methanol, approximately 10 ng / ml) to each sample sequentially, vortex to mix for 2 min, and then centrifuge at 12000 rpm for 10 min at 4 °C. 3) Take the supernatant for LC / MS / MS analysis.

[0332] Analytical conditions: Liquid chromatography: Shimadzu Nexera X2; Column: Agilent ZORBAX XDB-C18 3.5 (2.1×50mm); Column temperature: 35℃; Mobile phase: A-5% acetonitrile (0.1% formic acid aqueous solution), B-95% acetonitrile (0.1% formic acid aqueous solution); Injection volume: 3μL;

[0333] Flow rate: 0.5 mL / min. Gradient elution was used, and the elution program is shown in the table below.

[0334] Table 19

[0335]

[0336] Mass spectrometry conditions: Electrospray ionization (ESI) was used for mass spectrometry analysis in positive ion and multiple reaction monitoring (MRM) mode. The mass spectrometry ion source parameters and compound detection parameters are shown in the table below.

[0337] Mass spectrometry ion source parameters

[0338] Table 20

[0339] instrument Triple Quad™ 6500+AB mass spectrometer, made in Canada. Ion source mode ESI Scanning mode MRM Curtain air 20L / min atomized gas 50L / min Auxiliary Qi 50L / min Ion source temperature 300℃ Ion spray voltage +5500v (positive MRM)

[0340] The main scanning parameters for the analytes and internal standards are shown in the table below.

[0341] Table 21

[0342] Compound Name Q1(m / z) Q3(m / z) DP(v) EP(v) CE(v) CXP(v) Formula I compound 391.1 159.1 135 10 50 15 IS (verapamil) 455.3 165.2 135 10 35 15

[0343] PK parameter processing: Based on the blood drug concentration and corresponding sampling time data of each individual, the software PhoenixWinNonlin was used to calculate the pharmacokinetic (PK) parameters based on the blood drug concentration using a non-compartmental model. (1) The PK parameters used to evaluate pharmacokinetics include: Cmax, AUC0-t, AUC0-∞, Tmax, and t1 / 2.

[0344] (2) Used for bioequivalence evaluation: Cmax, AUC0-t, and AUC0-∞ are used for bioequivalence evaluation.

[0345] Cmax: The maximum blood drug concentration measured within a specified time period, which is the measured value.

[0346] Tmax: The time to peak plasma concentration, which is the measured value. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.

[0347] AUC0-t: Area under the blood drug concentration-time curve from point 0 to the last time point t.

[0348] AUC0-∞: Area under the plasma concentration-time curve from zero to infinity. Ct is the last measured concentration, and λz is the terminal phase elimination rate constant.

[0349]

[0350] t1 / 2: Elimination or terminal half-life, estimated by ln2 / λz.

[0351] Results: The linear range of compound I was 2-2000 ng / ml. The plasma concentrations of compound I (crystalline form A) and compound I (amorphous form) in rats over time after administration of 10 mg / kg are shown in Tables 22 and 23, respectively. Figure 14 and Figure 15 The main pharmacokinetic parameters in rats are shown in Tables 24 and 25.

[0352] Table 22: Blood concentration-time data of rats administered 10 mg / kg of compound I (crystal form A)

[0353]

[0354] Table 23: Blood concentration-time data of rats administered 10 mg / kg of compound I (amorphous).

[0355]

[0356] Table 24. Partial pharmacokinetic parameters of rats after gavage administration of compound I (crystal form A) at 10 mg / kg.

[0357]

[0358] Table 25. Partial pharmacokinetic parameters of rats after gavage administration of compound I (amorphous) at 10 mg / kg.

[0359]

[0360] After rats were orally administered the same dose of compound I (crystalline form A) or compound I (amorphous form), the Cmax was 578 ng / ml and 151 ng / ml, respectively; the AUClast was 4734 h* ng / ml and 1077 h* ng / ml, respectively. The difference between the two was significant (p < 0.05), indicating that the bioavailability of crystalline form A was significantly higher than that of amorphous form.

[0361] The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiments. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention. All documents mentioned in the present invention are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various alterations or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims.

Claims

1. A pharmaceutical composition comprising: Crystal form A of the monohydrate of compound I Formula I and pharmaceutically acceptable excipients; The crystal form A has characteristic peaks at 9.35±0.2°, 11.42±0.2°, 12.06±0.2°, 18.71±0.2° and 21.16±0.2° in the X-ray powder diffraction pattern expressed in 2θ angles; The pharmaceutical composition comprises the following components in parts by weight: 。 2. The pharmaceutical composition according to claim 1, wherein the crystal form A has characteristic peaks at 9.97±0.2°, 13.16±0.2°, 19.15±0.2°, 19.97±0.2° and 21.00±0.2° in the X-ray powder diffraction pattern expressed in 2θ angles.

3. The pharmaceutical composition according to claim 1, wherein the crystal form A has an X-ray powder diffraction pattern substantially as shown in FIG5.

4. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is prepared as an oral formulation.

5. The pharmaceutical composition according to claim 1, wherein the crystal form A has a thermogravimetric analysis spectrum and a differential scanning calorimetry spectrum as shown in FIG6.

6. The pharmaceutical composition according to claim 1, wherein the crystal form A is a monoclinic crystal system, space group P2(1), with cell parameters a=10.2499(10) Å, b=17.9931(16) Å, c=11.2407(8) Å, α=γ=90°, β=93.349(8)°, deviation factor R1=0.0562, and Z=4.

7. The pharmaceutical composition according to claim 1, wherein the D90 of crystal form A is 17-523 μm.

8. The pharmaceutical composition according to claim 1, wherein the D90 of crystal form A is 17-191 μm.

9. The pharmaceutical composition according to claim 1, wherein the first diluent is selected from mannitol, lactose, anhydrous calcium hydrogen phosphate, or a combination thereof.

10. The pharmaceutical composition according to claim 1, wherein the second diluent is microcrystalline cellulose.

11. The pharmaceutical composition according to claim 1, wherein the flow aid is colloidal silica.

12. The pharmaceutical composition according to claim 1, wherein the disintegrant is selected from sodium carboxymethyl starch, croscarmellose sodium, croscarmellose, or a combination thereof.

13. The pharmaceutical composition of claim 1, wherein the lubricant is selected from sodium stearate, magnesium stearate, or a combination thereof.

14. The pharmaceutical composition of claim 1, wherein the coating material comprises a stabilizing agent and a polymer, wherein the stabilizing agent is selected from at least one of titanium dioxide, talc and yellow iron oxide, and the polymer is selected from at least one of polyvinyl alcohol and polyethylene glycol.

15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition has one or more of the following characteristics: 1) Under conditions of pH 6.0-7.6 and 0.2% SDS, the dissolution rate of crystal form A in the pharmaceutical composition is ≥70% within 15 minutes; 2) Under conditions of pH 6.0-7.6 and 0.2% SDS, the dissolution rate of crystal form A in the pharmaceutical composition is ≥85% within 45 minutes; 3) Under conditions of pH 6.0-7.6 and 0.2% SDS, the dissolution rate of crystal form A in the pharmaceutical composition is ≥95% within 60 minutes; 4) When the pharmaceutical composition is stored at 25±2℃ and 60%±5%RH for 18 months, the dissolution rate of crystal form A in the pharmaceutical composition is ≥85% within 45 minutes; 5) When the pharmaceutical composition is stored at 40±2℃ and 75%±5%RH for 6 months, the dissolution rate of crystal form A in the pharmaceutical composition is ≥85% within 45 minutes.

16. The pharmaceutical composition of claim 1, wherein the excipient is a carrier.

17. The pharmaceutical composition of claim 1, wherein the excipient is an excipient.

18. A method for preparing the pharmaceutical composition according to any one of claims 1-17, comprising: The following materials are provided in parts by weight as raw materials and said raw materials are prepared into a composition: 。 19. The preparation method according to claim 18, wherein the preparation method comprises: The following materials are provided in parts by weight as raw materials and said raw materials are prepared into a composition: 。 20. The preparation method according to claim 18, wherein the D90 of crystal form A is 17-523 μm.

21. The preparation method according to claim 18, wherein the D90 of crystal form A is 17-191 μm.

22. The preparation method according to claim 18, wherein the first diluent is selected from mannitol, lactose, anhydrous calcium hydrogen phosphate, or a combination thereof.

23. The preparation method according to claim 18, wherein the second diluent is microcrystalline cellulose.

24. The preparation method according to claim 18, wherein the flow aid is colloidal silica.

25. The preparation method according to claim 18, wherein the disintegrant is selected from sodium carboxymethyl starch, croscarmellose sodium, croscarmellose, or a combination thereof.

26. The preparation method according to claim 18, wherein the lubricant is selected from sodium stearate fumarate, magnesium stearate, or a combination thereof.

27. The preparation method of claim 18, wherein the coating material comprises a stabilizing agent and a polymer, wherein the stabilizing agent is selected from at least one of titanium dioxide, talc and yellow iron oxide, and the polymer is selected from at least one of polyvinyl alcohol and polyethylene glycol.

28. The preparation method according to claim 18, wherein the preparation method of crystal form A is to pulp the compound of formula I using a mixed solvent of acetonitrile and water.

29. The preparation method according to claim 18, wherein the preparation method of crystal form A is to slurry the compound of formula I using a mixed solvent of acetonitrile and water for 1-4 days, and then collect the crystalline powder solid by centrifugation.

30. Use of the pharmaceutical composition of any one of claims 1-17 in the preparation of an anticancer or antitumor medicament for treatment and / or prevention; wherein the anticancer or antitumor medicament targets a cancer or tumor selected from breast cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, brain cancer, prostate cancer, kidney cancer, melanoma, glioma, glioblastoma, head and neck cancer, papillary renal tumor, leukemia, and thyroid tumor.

31. Use of the pharmaceutical composition of any one of claims 1-17 in the preparation of a medicament for treating and / or preventing ROS1, NTRK, ALK-mediated diseases; wherein the ROS1, NTRK, ALK-mediated diseases are selected from colon cancer, lung cancer, gastric cancer, rectal cancer, brain cancer, prostate cancer, kidney cancer, melanoma, glioma, glioblastoma, head and neck cancer, papillary renal tumor, leukemia, thyroid tumor, and sarcoma.